New Product Launch

Home » New Product Launch

Beacon produces Pandovir 100 injection to treat Covid-19 patients

Beacon Pharmaceuticals Limited (BPL) has launched Pandovir 100, a broad-spectrum antiviral medicine, for the treatment of severe Covid-19 cases under the generic of Remdesivir. The BPL launched the generic version of Remdesivir in august in view to provide drug or treatment of Cvid 19 patient in August. Directorate General of Drug Administration (DGDA) considered it [...]

By |2020-10-14T05:27:11+00:00October 14th, 2020|New Product Launch|0 Comments

Beacon Medicare Limited launches Pembroxim for the treatment of Cancer Immunotherapy

Beacon Medicare Limited (BML) has recently launched a new product under the brand name “Pembroxim”, in injection form, under the generic of Pembrolizumab, to help patients fighting against the infection of certain types of cancer in the world. The medicine will be used in cancer immunotherapy that includes melanoma, head and neck cancer, Hodgkin lymphoma [...]

By |2020-07-29T06:52:48+00:00July 29th, 2020|New Product Launch|0 Comments

Beacon is delighted after launching Multiple Tyrosine Kinase Inhibitor (TKI), Pazonix that is only for the treatment of renal cell carcinoma

Beacon Medicare Limited, a number one oncology company in Bangladesh, has launched Pazonix in tablet form under the generic of Pazopanib, an anti-cancer drug, only for export purpose in the world market. Pazonix ( pazopanib) is one of the most advanced & latest drug for the treatment of Renal Cell Carcinoma. This is the global [...]

By |2020-09-28T03:31:14+00:00July 29th, 2020|New Product Launch|0 Comments

Beacon Medicare Limited has launched Blockbuster drug Nivolunix for Non Small Cell Lung Cancer patients.

Beacon Medicare Limited has launched Nivolunix in injection form under the generic of Nivolumab, for treating certain types of cancer. The product was prepared only for export purpose. The medicine will be available in two strengths –40mg/4ml and 100mg/10ml –injections and a vial of the injection. Nivolunix is a humanized antibody that is used in [...]

By |2020-07-29T06:53:43+00:00July 29th, 2020|New Product Launch|1 Comment

Megahit Product Nilonix has successfully launched by Beacon for the treatment of Philadelphia chromosome-positive CML for export purpose.

Beacon Medicare Limited has announced the launching of Nilonix in capsule form under the generic of Nilotinib for the treatment of people, who diagnosed with Philadelphia chromosome positive CML and limatinib resistant Ph+ CML, effectively. The medicine will be available in two strengthens –150mg and 200mg --capsule and the both packets will contain 120 capsules [...]

By |2020-09-28T03:31:14+00:00July 29th, 2020|New Product Launch|0 Comments

Beacon proudly introduces highly potent multi-targeted third generation BCR– ABL Tyrosine Kinase Inhibitor Ponatinib(Ponatinix)

We are pleased to inform you that Team BML is going to launch Ponatinix Tablet for global market. It will be available in two strengths (45 mg and 15 mg). Each pack of Ponatinix 45 will contains 30 tablets and Ponatinix 15 will contains 60 tablets in HDPE pot. The product is only for global [...]

By |2020-09-28T03:31:15+00:00December 9th, 2019|New Product Launch|0 Comments

Beacon introduced another block buster drugs Cabozanitib

BEACON introduced another promising multiple Tyrosine kinase inhibitor, Cabozanitib, under the brand name of Cabozanix for global market. Cabozanitibis an anticancer drug for: Renal Cell Carcinoma Metastatic Thyroid Cancer Cabozanix is an oral Capsule  preparation which is available in the strengths of 20 mg &80mg. Each pack Cabozanix 20 contains 90 capsules and Cabozanix 80 [...]

By |2019-07-03T13:18:24+00:00July 3rd, 2019|New Product Launch|0 Comments

Blockbuster product “Hernix” has successfully launched

Hernix is a kinase inhibitor indicated for: Treatment of adult patients with early stage HER2 overexpressed breast cancer. Hernix can reduce risk of recurrence following Tastuzumab based therapy. Improve disease free survival Significant treatment benefit at 5 years. It is an oral tablet production available in the strength of 40 mg. This product is only [...]

By |2020-09-28T03:31:16+00:00July 3rd, 2019|New Product Launch|0 Comments

Beacon introduced another block buster drugs Obetix for Cirrhosis Treatment

Beacon Medicare Ltd. introduced another block buster drugs Obetix for Cirrhosis Treatment: BEACON introduced a Farnesoid X Receptor agonist , Obeticholic Acid, under the brand name of Obetix  for the treatment of Primary Biliary Cirrhosis .. Obetix  is a general drugin oral tablet preparation available in the strength of 5 mg. This product is only [...]

By |2020-09-28T03:31:17+00:00July 3rd, 2019|New Product Launch|0 Comments

BEACON proudly introduced yet another blockbuster drug, Lenvatinib

BEACON introduced another promising multikinase inhibitor, Lenvatinib, under the brand name of Lenvanix for global market. Lenvatinib is an anticancer drug. It is the First new Front-Line treatment option for Hepatocellular Carcinoma (HCC) approved in Japan in nearly 10 years. First TKI to demonstrating Complete Response (CR) in a phase 3 trial for locally recurrent [...]

By |2020-09-28T03:31:17+00:00July 7th, 2018|New Product Launch|0 Comments

Beacon Pharmaceuticals ltd offers Xonimide under the generic of Zonasamide

Beacon Pharmaceuticals ltd offers Xonimide under the generic of Zonasamide, an antiseizure agent which indicated as Monotherapy in the treatment of partial seizures ,with or without secondary generalization, in adults with newly diagnosed epilepsy Adjunctive therapy in the treatment of partial seizures, with or without secondary generalization, in adults, adolescents, and children aged 6 [...]

By |2020-09-28T03:31:17+00:00July 7th, 2018|New Product Launch|0 Comments

Beacon introduces new drug Eltrombopag for the treatment of thrombocytopenia

BEACON Pharmaceuticals Limited introduced Eltrombopag under the brand name of ETP for the treatment of thrombocytopenia. Eltrombopag (ETP) is approved by USFDA for the following indications- Thrombocytopenia in adult and pediatric patients of 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP). Thrombocytopenia in patients with chronic hepatitis C. Patients with severe aplastic. ETP [...]

By |2020-09-28T03:31:17+00:00July 10th, 2017|New Product Launch|0 Comments

Tetrabenazine 25mg tablet launched by Beacon

Beacon Pharmaceuticals Limited introduces Tetrabenazine 25mg tablet  under  the Brand name Tetrazine 25. Tetrabenazine is a monoamine depleter.Tetrazine  25mg tablet will be used for the treatment of Hyperkinetic Movement Disorder. Tetrazinabine is available in  12.5 mg tablet also.

By |2020-09-28T03:31:17+00:00June 13th, 2017|New Product Launch|0 Comments

Multivitamin Syrup launched by Beacon

Beacon Pharmaceuticals Limited introduces Multivitamin Syrup with Cod Liver Oil in the Brand name DORAKID (Syrup). The Syrup is a vital supplement for growing Kids. DORAKID is a multivitamin and mineral supplement indicated for malnutrition symptoms of children like weakness, common sickness, less memorizing power and inattentiveness DORAKID Syrup is highly palatable liked by children.

By |2020-09-28T03:31:17+00:00February 15th, 2017|New Product Launch|0 Comments

Beacon Pharmaceuticals Limited introduces Deflazacort 24 first time in Bangladesh

Beacon Pharmaceuticals Limited introduces Deflazacort INN 24 mg Tablet under the brand name of Xalcort 24. Xalcort 24 is going to be the 1st preparation of Deflazacort 24 mg tablet in Bangladesh.  Xalcort 24 is a Corticosteroid preparation drug which is used as anti- inflammatory & immunosuppressant. In acute conditions, dose of Deflazacort is initially up to [...]

By |2020-09-28T03:31:18+00:00August 7th, 2016|New Product Launch|Comments Off on Beacon Pharmaceuticals Limited introduces Deflazacort 24 first time in Bangladesh